PHARMACEUTICALS

FOCUSED ON AI

& NOVEL DRUG

ALTERNATIVES

LEADERS

IN DRUG

DESIGN

OUR PARTNERS

CPS.png
Wuxi.PNG
images.png
biomea.PNG
Charles-River.png
insilico.png

At A2A Pharmaceuticals, our mission is to leverage proprietary computational systems, including A.I., to accelerate development of novel drug alternatives for life threatening diseases like cancer, bacterial infections and muscular dystrophy.

Significant Achievements to Date

2020

Raised $55M for BIOMEA FUSION spin-off company focused on MLL-Menin.

Partnership with Laxai to  Develop Mpro Inhibitors for  the Treatment of COVID-19

2018

2019

Partnership with DAEWOONG Pharmaceutical to develop oncology therapeutics.

Partnership with Insilico Medicine to develop a novel therapeutics for Duchenne Muscular Dystrophy. 

2018

Raised a Total of $5M in Financing with $3.7M Directly in A2A

Awarded Johnson & Johnson Innovation and Janssen Research & Development's Artificial Intelligence for Drug Discovery Quickfire Challenge.

Biomea JV Formation for Taking the  MLL-Menin program into IND with  former Pharmacyclics management

2017

2016

Revenue generating pilot projects with Novartis and Proctor & Gamble to sign new drug candidates.

Seed funding through SOSV and incubation at IndieBio.

 Pipeline overview

TECHNOLOGY

Sculpt.png